Michael Lahn

Michael Lahn

Company: iOnctura

Job title: Chief Executive Officer


Biomarker Strategies to Identify Patients With Resistance to Current Immunotherapies 11:40 am

• Review the current understanding on what determines resistance to immunotherapies • Summary of available biomarker strategies • Show cases/examples on how to detect resistance mechanisms in patients (such as Tregs, MDSCs, CAFs) • Impact on current oncology clinical trial endpointsRead more

day: Day 1 red

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.